AZD 9496

Drug Profile

AZD 9496

Alternative Names: AZD9496

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer

Most Recent Events

  • 10 Aug 2017 AstraZeneca plans a phase I trial for Breast cancer in Germany and United Kingdom (NCT03236974)
  • 06 Dec 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 06 Dec 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 39th Annual San Antonio Breast Cancer Symposium (SABCS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top